The ongoing phase 2 study ATARI is investigating the impact of olaparib (PARPi) monotherapy and in combination with an ATR inhibitor drug (AZD6738) in gynecological cancers and compares tumors with and without ARID1A loss (NCT04065269). This evidence concerns the gene ATR and female reproductive organ cancer.